Interface Biologics

Interface Biologics

Interface Biologics

Develops transformative biomedical polymer technology to improve safety of med device. Focused on anti-thrombogenic additives and combo drug delivery devices.
Founded
2001
Raised
$32M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
Undisclosed amount
Venture capital (Series B) - 2015
BDC Capital DSM Venturing
$1,000,000
Venture capital - 2011
Team Size
1–10
Employees
Location
Headquarters
Venture capital (Series B)
sys-con

Interface Biologics Announces Series B Financing Round With DSM and BDC Capital